Baird Upgrades Theravance Biopharma (TBPH) to Neutral, Says Trelegy Royalty Offers Valuation Backstop
Tweet Send to a Friend
Baird analyst Brian Skorney upgraded Theravance Biopharma (NASDAQ: TBPH) from Underperform to Neutral with a price target of $18.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
